The patient had no history of liver or biliary disease, alcohol abuse or drug addiction, had no exposure to liver viruses and had not travelled to any exotic locations. In view of these findings, we decided to withdraw the MPS again, and rule out other causes of liver involvement.
After that withdrawal, the transaminase levels had returned to normal. We also found that this enzyme abnormality was already present, although to a lesser extent (GOT 21, GPT 85 and GGT 250 IU/l), before the temporary withdrawal of the drug due to the peritonitis ( Fig. Reviewing previous blood tests results, we found that the elevation of transaminases coincided with the restart of treatment with MPS. The patient denied having any symptoms and had no signs of jaundice or hepatomegaly. Two weeks after reintroducing the MPS, follow-up bloods showed elevation of transaminases (GOT 44, GPT 158 and GGT 455 IU/l), with normal bilirubin, albumin and coagulation.
Once the peritonitis had resolved, and having already begun the oral prednisone tapering regimen, it was decided to reintroduce the MPS in smaller doses (180 mg/day).
The mycophenolate was discontinued and antibiotic treatment started with intraperitoneal vancomycin, for 15 days, with a favourable response and outcome.Ī month after starting treatment for the vasculitis flare-up, the patient’s ANCA values were negative and her CRP had returned to normal. After two weeks of treatment with MPS, the patient developed peritonitis caused by Enterococcus Faecium. Chest X-ray revealed bilateral and multifocal pseudonodular parenchymal opacities, confirmed on chest CT, highly suggestive of bleeding, which was confirmed by bronchoscopy with bronchoalveolar lavage.Īs a new flare-up of her vasculitis was suspected, treatment was started with boluses of methylprednisolone and then, after evident clinical and radiological improvement, was continued with oral prednisone (60 mg/day) to which MPS (180 mg/12 h) was added as a supplementary therapy. In the initial investigations, blood tests showed normal blood count, clinical biochemistry consistent with the patient’s renal failure, ANCA of 34, CRP 68 and normal complement. Then in June 2018 she developed severe asthenia, arthralgia and an irritative cough, which was causing haemoptysis within a few days. Given the stability of her condition, and the fact that she was already on dialysis, the decision was made to discontinue azathioprine after two years of treatment. She had remained on peritoneal dialysis since then, without any incidents of note for three and a half years. After the second flare-up, the deterioration in renal function persisted and continued to progress over the following year until she had to begin peritoneal dialysis (October 2014). A year and a half later (May 2013) the patient had a second flare-up, again with pulmonary haemorrhage and renal dysfunction, which once again was treated with steroids and cyclophosphamide bolus, subsequently starting maintenance treatment with azathioprine. She was treated with steroids and oral cyclophosphamide, with almost total recovery of her previous renal function. This was a 68-year-old woman, diagnosed seven years previously (November 2011) with polyarteritis nodosa (PAN) vasculitis with MPO-ANCA serology which presented in the form of pulmonary and renal involvement. We present what we believe is only the second published case of acute hepatitis associated with MPS. The sodium formulation, with intestinal and not gastric absorption, was developed to reduce the incidence of gastrointestinal adverse effects.Īlthough gastrointestinal intolerance is common, published cases of liver involvement are very rare, and almost always associated with MMF. There are two different pharmaceutical forms: as ester, mycophenolate mofetil (MMF) and as sodium salt, mycophenolate sodium (MPS). Mycophenolic acid is generally well tolerated and its most notable adverse effects are gastrointestinal (nausea, vomiting, diarrhoea) and haematological (leucopenia, anaemia and thrombocytopenia).
0 kommentar(er)
